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Background: Epicardial ablation concomitant to cardiac surgery is an easy and safe approach to treat atrial
fibrillation (AF), but its efficacy in longstanding persistent (LsPe) AF remains intermediate. Although larger left atrial
size has been associated with worse outcome after ablation, biochemical predictors of success are not well
established. The aim of this study was to evaluate relationship between biochemical marker, echo-characteristic and
cardiac rhythm in 6 months follow-up after epicardial ultrasound (HIFU) ablation.
Methods: We included 78 consecutive patients, who underwent elective cardiac surgery. 42 patients with AF
(11.9% paroxysmal, 23.8% persistent, 64.3% LsPeAF) underwent concomitant HIFU ablation (AF ablation group), 16
with AF underwent cardiac surgery without ablation (AF control) and 20 had preoperatively normal sinus rhythm
(SR control). We measured plasma ANP secretion before, on postoperative day (POD) 1, POD 7 as well as 3 and 6
months after surgery. Moreover, we estimated cardiac rhythm and atrial mechanical function by Atrial Filling
Fraction (AFF) and A-wave velocity in follow-up.
Results: Baseline ANP levels were higher in patients with LsPeAF, as compared to the paroxysmal and permanent
AF and to the SR control group. Patients with LsPeAF (n = 27) who converted to SR had preoperatively smaller left
atrial diameter (LAD) and LA area (p < 0.05) and higher ANP level (p = 0.009) than those who remained in AF at 6
months after ablation. Multivariate regression analysis revealed that only preoperative ANP level was an
independent predictor of cardiac rhythm after ablation. Patients with LsPeAF and preoperative ANP >7.5 nmol/l
presented with SR in 80%, in contrast to those with ANP <7.5 nmol/l who converted to SR in 20%. We detected
gradual increase of AFF and A-velocity at 6 months after ablation (p < 0.05) solely in AF ablation group. ANP levels
were increased on POD 1 in ablation group (p < 0.05), without changes in further follow-up.
Conclusion: Our results indicate that preoperative ANP levels may be a new biochemical predictor of successful
epicardial ablation in patients with concomitant LsPeAF. HIFU ablation caused a significant improvement of atrial
mechanical function and gradual increase of AFF and did not associate with alteration of atrial endocrine secretion
at 6 months follow-up.
Keywords: Atrial fibrillation, Cardiac surgery, Atrial natriuretic peptide, Surgical ablation, Epicardial ablation, HIFU* Correspondence: pizon.marek@gmail.com
1Department of Cardiac Surgery, Clinic of Bayreuth, Preuschwitzerstr 101,
95455 Bayreuth, Germany
3Center of Cardiac Surgery, University Hospital of Erlangen, Krankenhausstr
12, 91054 Erlangen, Germany
Full list of author information is available at the end of the article
© 2013 Pizon et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Pizon et al. Journal of Cardiothoracic Surgery 2013, 8:218 Page 2 of 12
http://www.cardiothoracicsurgery.org/content/8/1/218Background
Atrial fibrillation (AF) is the most common supraven-
tricular cardiac arrhythmia, which affects approximately
6–10.2 million people in Europe, 2.2 million Americans
and its prevalence increases with age [1,2]. Affected pa-
tients have a five times bigger stroke risk and twice the
risk of death. AF reduces left ventricular (LV) function,
diminishes exercise tolerance, cognitive capacity, impairs
quality of life (QoL) as well as elevates atrial natriuretic
peptide (ANP) secretion [3-5]. In cardiac surgery AF is
associated with increased risk of perioperative death and
decreased short- and long-term survival [6].
AF is classified as paroxysmal (Pa; self terminating
within 7 days or cardioverted ≤48 hours), persistent (Pe;
sustained >7 days or cardioverted after 48 hours but
prior to 7 days), longstanding persistent (LsPe; continu-
ous >1 year) and permanent (continuous >1 year, pres-
ence of AF is accepted and the therapy does not affect
the restoration of sinus rhythm by any means) [7].
Current guidelines recommend concomitant surgical
ablation in patients with AF who undergo cardiac surgery
[1,7]. The procedure consists of formation of electrical
conduction blocks by scalpel like in classic Cox-maze pro-
cedure (CMP) or an alternative source of energy such as
high intensity focused ultrasound (HIFU), radiofrequency
(RF), cryoablation, microwave and laser. The aim is to
isolate trigger foci and inhibit macro-reentry circuits,
essential in pathogenesis of AF. HIFU allows epicardial ab-
lation on beating heart and its safety and efficacy is well-
known [8-12]. The primary goal of ablation is to restore
the active function of the atria, to improve cardiac
hemodynamics and reduce the risk of embolism. The suc-
cess of surgical ablation depends on type and duration of
AF and left atrium (LA) size [13,14]. Patients with LsPe
AF have the most enlarged atria and show generally the
poorest outcome after ablation [11,12].
Yoshihara et al. revealed that atrial natriuretic peptide
(ANP) might be a potential predictive marker of heart
rhythm after ablation by maze procedure [15]. ANP be-
longs to the group of natriuretic homeostatic peptides. It
increases diuresis and natriuresis, stimulates vasodilata-
tion, inhibits the renin-angiotensin-aldosteron system
(RAAS), the sympathetic nervous system and regulates
water balance. ANP is synthesized in atrial myocytes and
the key stimulus for its secretion in AF is the stretch of
atrial wall (rather than atrial pressure) [16].
Classic CMP has been reported to cause a dramatic
decrease of ANP levels for at least 7 days after proced-
ure, leading to post-operative severe fluid retention,
oedema and recurrent pleural effusion [17]. To our
knowledge, the effect of HIFU on post-operative plasma
ANP levels has not yet been studied. The biochemical
predictors of cardiac rhythm after epicardial ablation are
not yet known. The aims of our prospective study were:(1) to evaluate whether preoperative ANP level might
have a predictive value for the success rate of epicardial
HIFU ablation (2) to estimate the recovery of atrial
mechanical function following epicardial HIFU ablation
and their impact on alteration of endocrine secretion in
6 moths follow-up (3) to analyze the effect of epicardial
HIFU ablation of concomitant AF on atrial endocrine
secretion based on serial postoperative ANP levels.
Methods
Patients’ population
We conducted a prospective trial with ‘all-comers’ design
and included 78 consecutive patients, who underwent
elective cardiac surgery from 2011 to 2012. 42 patients
with AF due to organic heart disease underwent epicardial
HIFU ablation concomitant to cardiac surgery (AF ablation
group). 16 patients with AF due to organic heart disease
underwent cardiac surgery without ablation (AF control
group without ablation). 20 patients underwent cardiac
surgery and had normal sinus rhythm (SR control group).
Detailed baseline and operative characteristics of our study
population are presented in Table 1. Ablation was done in
all-comers design, i.e. patients were not selected in terms
of type and duration of AF, LA size and other parameters
important for treatment efficacy. Our study had an
“intention to treat”, i.e. ablation was offered to every pa-
tients affected with AF. Therefore AF control group with-
out ablation included only patients, in whom we found
intraoperative obstacles to safely perform the procedure.
Those were adhesions in re-operated patients or after
radiotherapy (breast cancer), chronic constrictive pericardi-
tis, left atrial myxomas (because of embolism risk at ma-
nipulation), endocarditis with aortic root abscess extending
into the dome of left atrium. One patient had dislodged left
atrial apandage occluder and other patient, with accepted
permanent AF for many years by himself and his cardiologist,
denied ablation, but agreed to cardiac surgery. The study was
approved by the research ethics committee of Friedrich-
Alexander University Erlangen-Nürnberg in Germany, and
all patients had given informed consent preoperatively.
AF type was classified according to current ACC/AHA/
ESC guidelines: paroxysmal (Pa), persistent (Pe), long-
standing persistent (LsPe) and permanent. According to
the guidelines, the term permanent AF refers to patients
for whom a decision has been made not to restore SR by
any means, including catheter or surgical ablation. Because
in our study every patient with AF was considered for sur-
gical ablation, patients previously classified as having per-
manent AF are in the following referred to as LsPe AF [8].
Exclusion criteria included significant systolic dysfunction
of the left ventricle with an ejection fraction (EF) <35%, renal
insufficiency with preoperative creatinine >2.0 mg/dl and
hyperthyroidism (TSH <0.3 μU/ml, fT4 >1.65 ng/ml, fT3
>4.0 pg/ml), as factors with a potential effect on ANP levels.
Table 1 Basal and operative characteristics of patients enrolled into the study
AF ablation group
(n = 42)
AF control group without





Age [years] 71.3 ± 8.3 73.8 ± 6.6 68.9 ± 7.0 0.16
Male gender, n (%) 31 (73,8%) 12 (75%) 15 (75%) 0.99
Body Mass Index (kg/m2) 29.4 (5.3) 27.5 (4.9) 29.2 (3.9) 0.38
AF duration [months] 64.8 ± 57.1 73.0 ± 92.9 0 0.291
Type of AF %, (n)
HRS/AHA (ACC: initial reclassified initial reclassified
1. Paroxysmal 11.9% 11.9% (5) 25.0% 25.0% (4) 0
2. Persistent 23.8% 23.8% (10) 31.2% 31.2% (5) 0
3. Longstanding pers. 21.4% 64.3% (27) 12.5% 43.7% (7) 0
4. Permanent 42.9% ———— 31.2% ———— 0
Cox - classification:
Intermittent 35.7% (15) 56.2% (9) 0 0.231
Continuous 64.3% (27) 43.7% (7) 0 0.231
Preop. cardioversion (DC), n (%) 11 (26.2%) 5 (31.2%) 1 (5%)
Preop. catheter ablation, n (%) 2 (4.8%) 0 0
Preop. perm. anticoagulation, n (%) 26 (61.9%) 9 (56.2%) 1 (5%)
Previous cardiac surgery 0 3 (18.75%) 0
Comorbidity, n (%)
Stroke 6 (14.3%) 2 (12.5%) 1 (5%)
Heart failure (CHF) 25 (59.5%) 10 (62.5%) 7 (35%)
Myocardial infarction 12 (28.6%) 5 (31.3%) 7 (35%)
Pre-op. creatinine [mg/dl] 1.3 ± 0.32 1.29 ± 0.35 1.09 ± 0.28 0.13
ECHO data
EF (Simpson) [%] 54.1 ± 10.8 54.1 ± 14.4 61.0 ± 9.0 0.07
Max. LA area [cm2] 27.7 (24.1-32.4) 27.8 (23.5-30.4) 20.3 (14.7-24.6) 0.651, p < 0.0012
Max. LA diameter (LAD) [mm] 48.5 ± 7.0 47.5 ± 7.2 41.7 ± 6.5 0.651, p < 0.012
LA AFF [%] 0 (0–25.2) 0 (0–34.9) 43.2 (32.4-52.8) p > 0.051, p < 0.0012
Procedures
Without mitral-surg., n (%) 32 (76%) 12 (75%) 18 (90%) 1.01,20.372
CABG 12 (28.6%) 2 (12.5%) 13 (65%)
AVR 7 (16.7%) 3 (18.75%) 5 (25%)
Aortic replacement 1 (2.3%) - -
AVR + CABG 11 (26.2%) 3 (18.75%) -
AVR + Aortic replacement - 2 (12.5%)
Aortic replacement + CABG 1 (2.3%) -
Tricuspid valve surgery - 1 (6.25%) -
VSD - 1 (6.25%) -
With mitral-surgery, n (%) 10 (23.8%) 4 (25%) 2 (10%) 1.01, 0.372
Euroscore II (%) 3.0 ± 2.36 4.3 ± 3.15 1.94 ± 1.54 0.0072
LAA Amputation, n (%) 9 (21.4%) 2 (12.5%) 1 (5%)
RAA Amputation, n (%) 42 (100%) 16 (100%) 20 (100%)
Abbreviations comment: AF atrial fibrillation, SR sinus rhythm, LA left atrium, AFF atrial filling fraction, AVR aortic valve replacement, VSD ventricular septal
defect, MV mitral valve, MVR mitral valve replacement, LAA left atrial appendage, RAA right atrial appendage; 1represents the differences between AF ablation
group and AF control group without ablation; 2represents the differences between AF ablation group vs SR control group and AF control group without ablation
vs SR control group. Values are demonstrated as mean ± SD or median (25–75 percentiles).
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All patients underwent median sternotomy, heparini-
zation, amputation of the right atrial appendage (RAA),
institution of extracorporeal circulation and cardio-
plegic cardiac arrest following institutional protocol.
For epicardial HIFU ablation we used the Epicor system
(St Jude Medical). The procedure occurred following
full heparinization and before institution of cardiopul-
monary bypass. The left atrial (LA) size was measured
to select the appropriate transducer and Ultra Cinch
was positioned through the transverse sinus. On beating
heart the posterior wall of left atrium around the pul-
monary veins was isolated in 10-minutes algorithm, cre-
ating so-called box lesion. In addition mitral line lesion
was created with the Ultra Wand (applied for 2 mins) in
all patients undergoing ablation.
Post-ablation treatment
Patients, who had undergone ablation, received a bolus
of 300 mg Amiodarone intraoperatively, followed by
continuous intravenous infusion for 24–72 hours and
oral therapy for at least 3 months. 3 months postopera-
tively the heart rhythm was reevaluated and amiodarone
therapy was stopped in patients with sinus rhythm or
continued in patients with ongoing AF. Maximal duration
of amiodarone therapy was 6 months. If contraindications
or bradycardia occurred, amiodarone therapy was inter-
rupted or continued with reduced dosage. Anticoagulation
was initiated 8 hours postoperatively with continuous
intravenous heparin infusion. On post-op day (POD) 2–3
the heparin drip was switched to oral Phenprocoumon
with a goal INR of 2.0-2.5. Patients remained anticoagu-
lated for at least 6 months postoperatively.
Measurement of plasma proANP (1–98)
For proANP (1–98) measurement peripheral blood was
collected 1 day preoperatively, and POD 1 and 7, as well
as 3 and 6 months after surgery. Blood was drawn fol-
lowing 20 minutes rest in supine position.
Blood samples were collected into EDTA tubes, placed
on ice, centrifuged at +4°C (40°F) within one hour and
the plasma was stored as aliquots at −80°C (−112°F)
until analyzed. The quantitative determination of plasma
proANP (1–98) concentration was performed using an
ELISA kit (Biomedica, Austria) following the manufac-
turer’s directions. The lower detection limit for pro ANP
(1–98) was 0.05 nmol/l and the intra- and inter-assay of
CV % were 2% and 4%, respectively.
Follow- up and echocardiography
Patients were seen at 3 and 6 months follow-up in our
clinic. The encounter included physical examination,
blood collection for ANP, ECG and transthoracic echo-
cardiogram (TTE). At 6 months follow-up additionallya 24 hour-ECG (Holter) monitoring was recorded. TTEs
were performed by standardized institutional protocol,
using Vivid 7 (General Electric, GE) and read by the
same experienced physician to minimize inter-rater
variability. In addition to standard evaluation of left
ventricular function, LA size was measured and he-
modynamic function of both atria was assessed. EF was
measured by Simpson method in two projections. Plani-
metric measurement of area and diameters (transverse
and longitudinal) of the left atrium was assessed in ap-
ical four-chamber view. For analysis of results the max-
imal transverse diameter of LA (LAD) and maximal LA
area (LA area) were used. Mechanical function of the
atria was analyzed in Pulsed-Doppler (PW) with meas-
urement of trans-mitral and trans-tricuspid inflow from
left and right ventricle, respectively. Velocity of A wave
on the level of mitral and tricuspid valve rings and
Atrial Filling Fraction (AFF) for the left atrium were
measured on the basis of average values from 3 con-
secutive cardiac cycles. AFF reflects the active contribu-
tion of the LA to diastolic filling of the left ventricle
(LV) and was calculated from percentage ratio of vel-
ocity time integral (VTI) for A wave to VTI of total dia-
stolic inflow.
Complete follow-up in the groups was done in 90.5%,
93.8% and 100% of patients (92,9%,100%,100% of survi-
vors) in the AF ablation group, AF control group with-
out ablation and SR control group, respectively.
Statistical analysis
All data are expressed as the means (±SD) or medians
(25–75 percentiles). Clinical data were analyzed by
unpaired Student t-test or the Mann–Whitney test.
ProANP (1–98) kinetic were evaluated by 1-way ANOVA
or ANOVA on ranks. Chi-Square test or Fisher’s exact
test was used to compare categorical variables between
groups.
We tested potential preoperative predictors of ablation
outcome in a three steps analysis. First, the impact on
binary ablation outcome (SR or AF) at 6 months of each
isolated parameter was studied in an univariate manner
using \Fischer exact test for 2 × 2 contingency tables.
Second, a multiple regression analysis was used to iden-
tify independent predictors of cardiac rhythm after abla-
tion. Thereafter, the quality and power of discrimination
was estimated by calculation of the area under the
receiver operating characteristic (ROC) curve. Cut-off
values of predictors were calculated for the best sensiti-
vityand specificity of tests. Assessment of Goodness of
Fit (GOF) for logistic regression model was ascertained
by the Hosmer-Lemeshow method [18].
p <0.05 was considered as significant. Statistical ana-
lyses were performed with SigmaPlot 11.0 for Windows
(Systat Software GmbH, Germany).
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Study groups and baseline clinical characteristics
Baseline characteristics are shown in Table 1. LAD be-
fore surgery was found increased according to the total
burden of AF: being lowest in SR control group (n = 20),
increased in Pa and Pe AF (n = 15) and largest in LsPe
AF (n = 27) (mean 41.7 ± 6.5 vs 46.2 ± 6.5 vs 49.7 ±
7.0 mm). Furthermore, in the group with LsPe AF LAD
was statistically significant larger than in SR control
group (p < 0.001). LA areas expressed a similar pattern
before the procedure, 20.3 cm2 (14.7-24.6) in SR control
group, 24.6 cm2 (22.3-27.5) in Pa and Pe AF and
28.0 cm2 (26.6-34.0) in LsPe AF. Solely in the group with
LsPe AF LA area was significantly larger in comparison
to SR controls (p < 0.001).
Results of ablation
In the AF ablation group (n = 42) no periprocedural
complications were observed. No death occurred within
30-days postoperatively. Two patients required pace-
maker implantation (4.7%) due to sick sinus syndrome
and chronotropic incompetence in 6 months follow-up.
Sinus rhythm (SR) was found in 66.7%/100% patients
with Pa AF, 100%/90% with Pe AF and in 33.3%/56%
with LsPe AF at 3 and 6 months. 68.4% of the patients
achieved freedom from AF and flutter within 6 months,
92.8% of patients with Pa and Pe, and 56% of patients
with LsPe AF. In AF control group without ablation SR
conversion rate was 0%/25% at 3 and 6 months after
cardiac surgery, respectively.
In patients with SR at 6 months after ablation, 84.6%
(22/26) and 88.5% (23/26) had an atrial-filling wave
(A-wave) in trans-mitral and trans-tricuspid inflow, re-
spectively, and both-side A waves were seen in 80.8% of
patients (21/26). A total lack of A wave was found in 2
patients with LsPe AF.
In AF ablation group we observed significantly im-
proved atrial mechanical function in follow-up. We
noted increased velocity of left-side A wave and AFF at
6 months, compared to the preoperative values (mean:
22.1 ± 39 and 11.5 ± 19.5 before ablation vs 37.2 ±
32.4 cm/s and 22.8 ± 17.1% after 6 months for A wave
and AFF, respectively, p < 0.05) (Figure 1). In contrast,
A-velocity and AFF did not show significant changes in
AF control group without ablation and in SR control
group.
Preoperative LAD and LA area as predictors of ablation
outcome
In AF ablation group patients who successfully con-
verted to SR at 6 months (n = 26) had preoperatively
smaller LAD (p = 0.01) and LA area (p = 0.02) than those
who remained in AF (n = 12). The cut-off point for LAD
was 50 mm, and LA area 29 cm2 (sensitivity 76.9%,specificity 66.6% and positive predictive value 83.3%). In
patients with LAD ≤ 50 mm and LA area ≤ 29 cm2 (n = 24),
effectiveness of ablation in restoring SR was 83.3% at
6 months and it was significantly higher compared to the
group with LAD> 50 mm and LA area > 29 cm2 (n = 14),
in which it was only 42.8% (p = 0.03) (Figure 2).
Kinetics of plasma ANP
Plasma ANP level changes in each group are shown in
Figure 3. In the AF ablation group ANP levels increased
significantly on POD 1 compared to the baseline (p = 0.04)
and did not show significant changes in further follow-
up. In the AF control group without ablation ANP levels
did not change significantly. However, in the SR control
group ANP levels increased significantly within 7 days,
then gradually decreased, reaching significant decrease
6 months after the procedure. ANP concentrations did
not significantly differ between the AF ablation group
and the AF control group without ablation during
follow-up. ANP levels in the AF ablation group were
higher compared to the SR control group, preopera-
tively (median 7.23 vs 3.78 nmol/l, p = 0.001), as well as
on POD 1 (median 9.34 vs 6.95 nmol/l, p = 0.04),
3 months (median 7.75 vs 5.55 nmol/l, p = 0.03) and
6 months postoperatively (median 8.98 vs 4.86 nmol/l,
p = 0.001). Whereas, in the AF control group without
ablation plasma ANP levels were higher in comparison
to the SR control group, preoperatively (median 7.24 vs
3.78 nmol/l, p = 0.03) and at 6 months follow-up (median
7.23 vs 4.86 nmol/l, p = 0.01).
Plasma ANP at baseline
Preoperative plasma ANP levels were considered as
baseline values. They were significantly higher in pa-
tients with AF (n = 58), as compared to individuals with
SR (n = 20) (p = 0.01). As shown in Figure 4, baseline
ANP concentrations were found with increasing levels
according to the total burden of AF, with being lowest in
the SR control group (n = 20), increased in patients with
Pa and Pe AF (n = 15) and highest in patients with LsPe
AF (n = 27). Patients with LsPe AF had significantly
higher baseline ANP levels, as compared to the patients
with Pa and Pe AF (mean 9.22 ± 4.0 vs 6.4 ± 2.7 nmol/l,
p = 0.01) and to the SR control group (mean 9.22 ± 4.0
vs 5.04 ± 3.6 nmol/l, p < 0.001).
In AF ablation group among individuals, who had SR
after 6 months (n = 26), we observed higher ANP con-
centrations before the operation and in follow-up, as
compared to the patients who remained in AF despite
ablation (n = 12), but the differences were not statisti-
cally significant.
Whereas in patients with LsPe AF (n = 27) we found sig-
nificantly higher preoperative plasma ANP levels in those
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A
Figure 1 Atrial mechanical function after ablation. (A) Atrial Filling Fraction (AFF) and (B) A-velocity of left atrium before, 3 and 6 months after
HIFU ablation.
Pizon et al. Journal of Cardiothoracic Surgery 2013, 8:218 Page 6 of 12
http://www.cardiothoracicsurgery.org/content/8/1/218compared to those who remained in AF (median 9.95
[7.53-14.02] vs 6.86 [5.68-8.06] nmol/l, p = 0.009) (Figure 4).
Preoperative ANP levels as predictor of cardiac rhythm
after ablation
To determine predictors of cardiac rhythm after HIFU
ablation in patients with LsPe AF (n = 27), we compared
preoperative variables between those individuals, who
had successfully converted to SR (n = 14) and those who
remained in AF (n = 11) at 6 months after procedure.
Preoperative ANP levels, LAD and LA area were signifi-
cantly higher, smaller and lower respectively in individ-
uals with SR than in those with AF at 6 months after
ablation (Table 2). Whereas preoperative duration of AF,
age and gender did not significant differ.
According to the multivariate logistic regression
analysis among preoperative variables only plasma
ANP level was an independent predictor of cardiac
rhythm after epicardial HIFU ablation in patients with
LsPe AF (Odds Ratio 0.733; Coefficient −0.31; p = 0.03)
(Table 3).
Finally, to test the performance of the predictors, we




















Figure 2 Impact of preoperative ANP, LAD and LA area on conversion
paroxysmal, persistent and longstanding persistent AF (B) preoperative pla
peptide; LAD: left atrial diameter; LA: left atrium.LAD and LA area. We found that the area under
the ROC curve (AUC) for baseline ANP levels was 0.79
(p = 0.013), for LAD 0.78 (p = 0.018) and for LA area
0.74 (p = 0.04). These findings indicate that, the pre-
operative ANP levels demonstrate high quality and
power as predictor of outcome after epicardial HIFU ab-
lation among patients with LsPe AF. Furthermore, pre-
operative plasma ANP was also more sensitive and had
better positive predictive value (PPV) in prediction of SR
after ablation (85.7% sensitivity, 80% PPV and 72,7% spe-
cificity for ANP at cut-off value 7.5 nmol/l) than the
classic echocardiographic parameters associated with LA
size (71.4% sensitivity, 76,9% PPV and 72,7% specificity
for LAD and LA area at cut-off 50 mm and 29 cm2,
respectively) (Figure 5).
In AF ablation group among patients with LsPe AF,
80% of individuals with a preoperative ANP level greater
than 7.5 nmol/l presented with SR at 6 months follow-
up. In contrast, only 20% of individuals with a baseline
ANP level below 7.5 nmol/l successfully converted to
SR after ablation (p = 0.005) (Figure 2). In patients with
Pa and Pe AF and baseline ANP levels >7.5 nmol/l we













rate at 6 months after ablation. (A) LA area and LAD in
sma ANP level in longstanding persistent AF; ANP: atrial natriuretic
before 1 day 7 days 3 months 6 months
AF ablation group 7,32 9,34 9,09 7,75 8,98
AF control without ablation 7,245 8,61 8,175 6,78 7,23

























Figure 3 Kinetics of plasma ANP in the study groups. Values are demonstrated as median.
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ANP levels <7.5 nmol/l, which however was not statisti-
cally significant.
Discussion
Our study is the first - to our knowledge - to evaluate
the relationship between a biochemical marker, echocar-
diographic characteristics and heart rhythm in 6 months
follow-up after epicardial HIFU ablation in patients with
concomitant AF undergoing cardiac surgery. Our results
indicate among patients with LsPe AF significantly
higher baseline ANP levels in individuals with successful
conversion to SR at 6 months follow-up after HIFU abla-
tion compared to patients, who remained in AF despite













































Figure 4 Preoperative ANP. (A) Comparison of the groups with longstan
persistent (PeAF) AF (n = 15) and SR control group (n = 20), (B) Comparison
longstanding persistent AF. ANP: atrial natriuretic peptide.noninvasive biochemical predictor of success after HIFU
ablation.
In addition, in LsPe AF, which revealed the lowest
conversion rate to SR among all types of AF [8] (in our
population 56% of SR after 6 months), patients with
baseline ANP levels > 7.5 nmol/l had high success rate of
SR restoration (80.0% after 6 months). In contrast in pa-
tients with baseline ANP levels < 7.5 nmol/l, the success
rate was significantly lower (20.0% after 6 months, p <
0.005). A similar relationship between preoperative ANP
levels and effectiveness of ablation by maze procedure
was also presented by Yoshihara et al. [15]. Sato et al.
showed a strong association between ANP-to-BNP ratio
and rhythm after the maze procedure in patients
with mitral valve disease [19]. Furthermore our results Mean 
 Mean±SD 
 Mean±1,96*SD SR AF
Rhythm at 6 months
p=0.009
B
ding persistent AF (Longst.Pe AF, n = 27), paroxysmal (PaAF) and
of individuals according to rhythm at 6 months after ablation in
Table 2 Preoperative characteristics of patients with
longstanding persistent AF
AF at 6 months SR at 6 months p value
Age (yrs) 78.0 (66.25-79.25) 74.5 (62.5-80.0) 0.87
Gender (male/female) 8/3 11/3 1.0
Duration of AF (yrs) 8.0 (3–10) 5.0 (3–9,5) 0.39
LAD (preop.) [mm] 53.1 ± 6.2 47.1 ± 6.2 0.01
LA area (preop.) [cm2] 33.95 (27.92-35.89) 27.84 (26.3-30.2) 0.03
ANP (preop.) [nmol/l] 6.86 (5.68-8.06) 9,995 (7.53-14.02) 0.009
Comparison of individuals converted to SR and remaining in AF at 6 months
after HIFU ablation.
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line plasma ANP levels are independent predictors of
cardiac rhythm after HIFU ablation in patients with LsPe
AF. Numerous studies reported that the patients with
successful SR restoration after classic maze procedure
had significantly smaller LAD as determined by pre-
operative echocardiography, than those who remained in
AF [19-21]. In our study, preoperative LAD with cut-off
at 50 mm was a dependent predictor of success after ab-
lation, which is consistent with previous reports [11,12].
In addition, we demonstrate that the patients with LsPe
AF those remained in AF despite HIFU ablation had not
only larger left atrial size (LAD >50 mm and LA area
>29 cm2) but also showed significantly lower preopera-
tive plasma ANP levels, compared to those who success-
fully converted to SR at 6 months. Furthermore our
study indicates that baseline plasma ANP levels in LsPe
AF are more useful for predicting the outcome of HIFU
ablation than conventional echocardiographic character-
istics, such as LAD and LA area.
We discovered an increase of plasma ANP level after
epicardial HIFU ablation, which is contrary to other
studies which described dramatically decreased ANP
levels after classic maze procedure (CMP) [17]. De-
creased ANP levels are the main cause for acute postop-
erative fluid retention with pulmonary oedema and
symptomatic pleural effusion observed in 12-36% of pa-
tients after CMP. On the other hand, higher ANP levels
are assumed to improve kidney function and prevent
renal insufficiency after cardiac surgery [21], have bene-
ficial impact on pulmonary pressure reduction [22] andTable 3 Multivariate logistic regression analysis
Cardiac rhythm at 6 months after HIFU ablation
Preop. Parameter Coefficient Odds ratio p value
LAD (mm) 0.204 1.227 0.135
LA area (cm2) −0.0174 0.983 0.90
ANP (nmol/l) −0.310 0.733 0.03
Associations between preoperative clinical parameters in longstanding
persistent AF and cardiac rhythm according multivariate logistic
regression analysis.protect against ischemia and reperfusion injury [23]. It is
believed that amputation of both atrial appendages in
the original Cox-maze procedure is a major cause of
postoperative ANP decrease [17]. Therefore, according
to Yoshihara et al. preservation of RAA in the modified
maze procedure effectively protects against postoperative
decrease of ANP and it has beneficial impact on the
postoperative course [21]. Hypothetically, an elevated
ANP level after HIFU ablation may have a beneficial ef-
fect on postoperative course, but this question requires
further investigations. In our study we amputated RAA
in 100% and LAA in 21.4% of cases, therefore the in-
creased ANP levels on POD 1 must be associated with
other factors than preservation of atrial auricles. Since
increased ANP levels from POD 7 to 3 months in
follow-up were also observed in the control group with
SR, we suspect that immediate postoperative ANP in-
crease is rather a reaction to surgical trauma, periopera-
tive higher volume load and atrial stretch. Other studies
revealed also similar increase of ANP levels observed on
POD 1 and 2 after CABG [24]. Surprisingly, cardiopul-
monary bypass and its duration did not influence plasma
ANP levels significantly [25]. Among patients with AF,
we observed a significant increase in postoperative ANP
levels only in the ablation group, but not in the control
group without ablation. We might hypothesize that
higher ANP concentrations could also be derived from
necrotizing wall injury due to ablation. Nevertheless,
among the individuals who did not undergo HIFU abla-
tion, we observed that patients in the SR control group
had a much greater increase in ANP levels on POD 1
than patients in the AF control group without ablation,
(83% vs 24% increase from baseline level). This might
suggest an impaired capability of the atria to release
ANP, when they are fibrillating. Systemic ANP level
depends not only on atrial stretching secondary to
hemodynamic changes, but also on structural state and
remodeling of atria. Previous study suggested that
plasma ANP levels in patients with AF reflected degen-
erative changes and inversely correlated with the level of
LA fibrosis [15]. Probably because the degenerative
changes are most expressed in LsPe AF, only in these pa-
tients preoperative plasma ANP levels were independent
predictors of cardiac rhythm after ablation in the present
study. While patients with Pa and Pe AF with intermit-
tent burden of atrial wall-stretch are heterogeneous as
for factors stimulating ANP release. It might explain,
why in our population we found the lowest basal plasma
ANP levels in the SR control group, increased in pa-
tients with paroxysmal and persistent and highest in pa-
tients with longstanding persistent AF. This data
partially confirmed the findings by Cao, which showed
elevated plasma ANP levels in paroxysmal and persistent
AF compared to SR group [5].
1 - Specificity
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Figure 5 ROC curves for predictors of outcome after epicardial HIFU ablation. (A) ROC curve for preoperative ANP level and (B) ROC curves
for LAD and LA area in long standing persistent AF. Baseline ANP level is the most useful predictor of heart rhythm at 6 months after HIFU
ablation in longstanding persistent AF; ROC: receiver operating characteristic; ANP: atrial natriuretic peptide; LAD: left atrial diameter; LA: left
atrium; AUC- area under the curve.
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hemodynamic active function, using echocardiographic
characteristics such as AFF and velocity of A-wave
in 6 months follow-up. The most important purpose
of surgical AF treatment is restoration of coordinated
atrial contraction and their transport function resulting
in improved cardiac hemodynamics, reduced risk of
thromboembolism and stroke [26]. In patients, who had
converted to SR at 6 months follow-up we observed ac-
tive contractility of both atria in 80.8% of patients, of the
left atrium in 84.6% and of the right atrium in 88.5%.
Previous studies had shown lower rates of recovery of
LA contractility in follow-up after ablation despite stable
SR, both in only left atrial ablation (70% for cryoabla-
tion) [27] and in biatrial ablation (63% for modified ra-
diofrequency Maze procedure) [28] or in CMP (73%)
[29]. However, there is no data in the literature on atrial
contractility after ablation using HIFU. We found signifi-
cant increase of both AFF and A wave velocity of the left
atrium in 6-months follow-up. These findings support
the assumption that left “atrial stunning” after epicardial
HIFU ablation last about 6 months and anticoagulation
is necessary throughout this time. We found no correl-
ation between recovery of LA contractility and ANP
level alteration (Figure 6). We suspect that the described
decreased ANP levels associated with SR restoration and
recovery of atrial contractility [30,31] are masked by
additional ANP release due to surgical trauma, necrosis
in ablated tissue or higher volume overload in the early
postoperative period.
68.4% of our entire study population achieved restor-
ation of SR within 6 months. This corresponds withstudies published recently (62-66% conversion rate)
[11,12]. However, our success rate was lower than the
first reports on HIFU-ablation (83.2%-85%) [8,10]. We
explain this by a lower percentage of individuals with Pa
AF in our study population (11.9%) compared to the
study of Groh et al. (33.3%) [10] and lower proportion of
patients with concomitant mitral valve surgery (23.8%)
in comparison to the study conducted by Ninet et al.
(44.6%) [8]. It is well-known that the success rate of ab-
lation is significantly higher in individuals with Pa AF
compared to those with LsPe and permanent AF, and
correction of mitral valve disease have a beneficial effect
on SR restoration [26]. We did not perform any positive
selection of patients regarding predictors of successful
ablation. In reality every patient with AF, who required
surgical treatment of underlying heart disease, has under-
gone concomitant ablation. This may result in the higher
proportion of LsPe and lower of Pa AF in our study.
Epicardial approach allows surgeons to replicate mini-
maze lesions on beating heart. It requires controlled
propagation of energy without risk of heart and collat-
eral structures damage or coagulates formation in circu-
lating blood. For this reason only the systems based on
RF, microwave and HIFU are suitable, whereas laser and
cryoablation can be used exclusively from endocardial.
Thickness of left atrial wall and epicardial fat layer [32]
and the “heat-sink effect” of circulating blood volume
are the main factors reducing transmurality and thereby
outcome of epicardial methods. Effectiveness of epicar-
dial ablations in restoring of SR by the same lines con-
cept are comparable and ranged between 62.2-65% for

















































































   


















Figure 6 ANP concentrations, AFF and A-velocity of LA after epicardial HIFU ablation. Significant increase of AFF and A-velocity at 6 months
compared to the baseline and no changes of ANP levels in 6 months follow-up. ANP: atrial natriuretic peptide; AFF: atrial filling fraction; LA:
left atrium.
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http://www.cardiothoracicsurgery.org/content/8/1/218for RF [34,35] at different follow-up periods. Following
the acquisition of Guidant company, production of Flex
4 and 10 sole devices using microwave was stopped.
Presently, the SJM company closed for business reasons
the branch of Epicor production in order to focus on
new market of transcatheter aortic valves technologies.
As a consequence actually only RF remains on the mar-
ket for epicardial approach.
Limitations
Our study population was relatively small with a patient
panel of 78 individuals, thereof 42 in the ablation group.
Nevertheless, the average number of patients included
in other studies [15,17,19,21,36] evaluating ANP and
surgical ablation was 37, ranging from 19 to 62 patients.
Our study was neither randomized controlled nor double-
blinded due to an intention to offer ablation to every
patient affected by AF. Therefore recruitment to the AF
control group without ablation was very difficult. Finally
our AF control group without ablation included only these
patients, in whom we found intraoperative obstacles to
safely perform the procedure which limited its size (n = 16)
and contributed to slightly higher risk in Euroscore II in
this group, as compared to the AF ablation group.
Conclusion
(1) Our results indicate that preoperative ANP levels
may be a new biochemical predictor of successful surgi-
cal HIFU ablation in patients with concomitant LsPe AF.(2) Surgical HIFU ablation of concomitant AF causes a
significantly improvement of atrial mechanical function
and gradual increase of AFF and did not associate with
alteration of atrial endocrine secretion at 6 months
follow-up. (3) Our results indicate that epicardial HIFU
causes an increased secretion of plasma ANP on POD 1.
Since drop of ANP after maze ablation is the main cause
of severe fluid retention, an ANP increase after HIFU
might have a beneficial impact on postoperative course;
however, further study is required to resolve this
question.
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